Jim Wilson and Tachi Yamada are at it again — launching a 2nd-gen gene therapy company with an appetite for risk, global vision and $200M to gamble with
When Tachi Yamada and Jim Wilson partnered on launching Passage Bio $PASG, the game plan was to use their considerable combined scientific knowhow and global …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
